AU2014207748B2 - Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders - Google Patents
Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders Download PDFInfo
- Publication number
- AU2014207748B2 AU2014207748B2 AU2014207748A AU2014207748A AU2014207748B2 AU 2014207748 B2 AU2014207748 B2 AU 2014207748B2 AU 2014207748 A AU2014207748 A AU 2014207748A AU 2014207748 A AU2014207748 A AU 2014207748A AU 2014207748 B2 AU2014207748 B2 AU 2014207748B2
- Authority
- AU
- Australia
- Prior art keywords
- metformin
- phenyl
- glp1r agonist
- agonist
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361753567P | 2013-01-17 | 2013-01-17 | |
| US61/753,567 | 2013-01-17 | ||
| PCT/US2014/011394 WO2014113357A1 (en) | 2013-01-17 | 2014-01-14 | Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014207748A1 AU2014207748A1 (en) | 2015-07-09 |
| AU2014207748B2 true AU2014207748B2 (en) | 2018-10-11 |
Family
ID=50030537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014207748A Active AU2014207748B2 (en) | 2013-01-17 | 2014-01-14 | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150313908A1 (https=) |
| EP (1) | EP2945618B1 (https=) |
| JP (1) | JP6445459B2 (https=) |
| KR (1) | KR102165434B1 (https=) |
| CN (1) | CN104968341B (https=) |
| AU (1) | AU2014207748B2 (https=) |
| CA (1) | CA2896308C (https=) |
| EA (1) | EA201591123A1 (https=) |
| ES (1) | ES2687083T3 (https=) |
| IL (1) | IL239714A0 (https=) |
| MX (1) | MX366685B (https=) |
| SG (2) | SG11201504778UA (https=) |
| WO (1) | WO2014113357A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3684793A1 (en) | 2017-09-22 | 2020-07-29 | Regeneron Pharmaceuticals, Inc. | Glucagon-like peptide 1 receptor agonists and uses thereof |
| MX2020008387A (es) * | 2018-05-08 | 2020-12-11 | Vtv Therapeutics Llc | Usos terapeuticos de agonistas glp1r. |
| US12459954B2 (en) | 2020-04-01 | 2025-11-04 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Crystalline form a of GLP-1 receptor agonist and preparation method therefor |
| JP2023528726A (ja) * | 2020-04-01 | 2023-07-06 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ１ｒアゴニスト遊離塩基の薬学的に許容される酸塩類およびその調製法 |
| US12582651B2 (en) * | 2020-12-31 | 2026-03-24 | Dong Kook Pharm. Co., Ltd. | Pharmaceutical composition comprising tadalafil or pharmaceutically acceptable salt thereof and dutasteride or pharmaceutically acceptable salt thereof exhibiting novel dissolution rate |
| WO2024064842A1 (en) | 2022-09-21 | 2024-03-28 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009111700A2 (en) * | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| WO2012156312A1 (en) * | 2011-05-13 | 2012-11-22 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 |
| US20120295846A1 (en) * | 2009-11-13 | 2012-11-22 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
| CA2628506A1 (en) * | 2005-11-07 | 2007-05-18 | Elixir Pharmaceuticals, Inc. | Combinations of metformin and meglitinide |
| CN102378574B (zh) * | 2009-03-30 | 2013-11-20 | 转化技术制药公司 | 取代的偶氮蒽衍生物、药物组合物及其使用方法 |
| US20110064806A1 (en) | 2009-09-11 | 2011-03-17 | Transtech Pharma, Inc. | Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same |
-
2014
- 2014-01-14 AU AU2014207748A patent/AU2014207748B2/en active Active
- 2014-01-14 JP JP2015553775A patent/JP6445459B2/ja active Active
- 2014-01-14 CA CA2896308A patent/CA2896308C/en active Active
- 2014-01-14 SG SG11201504778UA patent/SG11201504778UA/en unknown
- 2014-01-14 KR KR1020157018661A patent/KR102165434B1/ko active Active
- 2014-01-14 MX MX2015008555A patent/MX366685B/es active IP Right Grant
- 2014-01-14 EA EA201591123A patent/EA201591123A1/ru unknown
- 2014-01-14 ES ES14702159.6T patent/ES2687083T3/es active Active
- 2014-01-14 WO PCT/US2014/011394 patent/WO2014113357A1/en not_active Ceased
- 2014-01-14 CN CN201480004613.0A patent/CN104968341B/zh active Active
- 2014-01-14 SG SG10201704716XA patent/SG10201704716XA/en unknown
- 2014-01-14 EP EP14702159.6A patent/EP2945618B1/en active Active
-
2015
- 2015-06-30 IL IL239714A patent/IL239714A0/en unknown
- 2015-07-14 US US14/799,222 patent/US20150313908A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009111700A2 (en) * | 2008-03-07 | 2009-09-11 | Transtech Pharma, Inc. | Oxadiazoanthracene compounds for the treatment of diabetes |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| US20120295846A1 (en) * | 2009-11-13 | 2012-11-22 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| WO2012156312A1 (en) * | 2011-05-13 | 2012-11-22 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in the treatment of diabetes type 2 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015008555A (es) | 2016-01-22 |
| SG10201704716XA (en) | 2017-07-28 |
| CA2896308A1 (en) | 2014-07-24 |
| CA2896308C (en) | 2021-11-09 |
| MX366685B (es) | 2019-07-19 |
| IL239714A0 (en) | 2015-08-31 |
| WO2014113357A1 (en) | 2014-07-24 |
| EP2945618A1 (en) | 2015-11-25 |
| CN104968341A (zh) | 2015-10-07 |
| KR20150104572A (ko) | 2015-09-15 |
| AU2014207748A1 (en) | 2015-07-09 |
| JP2016505039A (ja) | 2016-02-18 |
| EA201591123A1 (ru) | 2015-11-30 |
| SG11201504778UA (en) | 2015-07-30 |
| JP6445459B2 (ja) | 2018-12-26 |
| ES2687083T3 (es) | 2018-10-23 |
| EP2945618B1 (en) | 2018-06-13 |
| US20150313908A1 (en) | 2015-11-05 |
| HK1210424A1 (en) | 2016-04-22 |
| CN104968341B (zh) | 2020-06-09 |
| KR102165434B1 (ko) | 2020-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014207748B2 (en) | Combinations of a GLP1R agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders | |
| KR101860120B1 (ko) | 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물 | |
| TWI918593B (zh) | Glp1r激動劑的治療用途 | |
| HK1210424B (zh) | Glp1r 激动剂和二甲双胍的组合及其在制备治疗 2 型糖尿病和其他障碍的药物中的用途 | |
| HK1181044B (en) | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: VTV THERAPEUTICS LLC Free format text: FORMER APPLICANT(S): VTV THERAPEUTICS LLC |
|
| FGA | Letters patent sealed or granted (standard patent) |